{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-009419","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.766878+00:00","generated_at":"2026-06-01T02:31:25.835722+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Scholar Rock presents SRK-439 preclinical data showing lean mass preservation and initiates Phase 2 EMBRAZE trial","bullets":["Preclinical DIO mouse study: SRK-439 with semaglutide preserved lean mass (26.4g vs 22.3g at 4 weeks, p<0.001) and increased relative lean mass (65.8%) after semaglutide withdrawal vs control (57.1%).","SRK-439 attenuated fat mass rebound after semaglutide withdrawal: relative fat mass 18.0% vs 28.7% (p<0.01) and reduced inguinal and epididymal adipose weights.","First participants dosed in Phase 2 EMBRAZE proof-of-concept trial of apitegromab in obesity patients on GLP-1 RA background therapy to assess lean muscle preservation.","Data presented at ADA 84th Scientific Sessions on June 23, 2024, supporting SRK-439's potential for healthier weight management and long-term metabolic benefits."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-009419","json":"https://secwatch.observer/filing/0001558370-24-009419.json","markdown":"https://secwatch.observer/filing/0001558370-24-009419.md","text":"https://secwatch.observer/filing/0001558370-24-009419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000155837024009419/0001558370-24-009419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000155837024009419/srrk-20240624x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:31:25.835722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}